Skip to main content
Premium Trial:

Request an Annual Quote

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested and charged with alleged involvement with a murder-for-hire case, Endpoint News reports.

Serhat Gumrukçu, the co-founder of Enochian BioSciences, was arrested for allegedly having a role in the 2018 death of a Vermont man, Gregory Davis, it adds. Davis was found dead in a snowbank a few miles from his residence in Vermont in January 2018. In addition to Gumrukçu, three other men have been arrested in connection with Davis's kidnapping and murder, which the Department of Justice describes in a press release as a murder-for-hire case.

Gumrukçu, Endpoint News says, has been credited with developing much of the technology underpinning Enochian, which develops gene-modified cell therapies for infectious diseases. In a statement, the company's board of directors calls the arrest "unexpected and shocking" and says "there is no link between the criminal charges and any actions of the company."

Endpoint News notes that, if convicted, Gumrukçu could face life in prison or the death penalty.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.